Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 237-241

  Mougenot, Philippe ^a   Fabbro, Michel ^b   Bressolle, Françoise ^a   Pouessel, Damien ^b   Culine, Stephane ^b   Pinguet, Frederic ^a  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

24 hour continuous infusion; Melphalan; Ovarian cancer; Response; Survival

Indexed keywords

ALKYLATING AGENT; MELPHALAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; EPITHELIUM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; EPITHELIUM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33644874966     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.237     Document Type: Article

References (42)

1. Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 10: 7439-7449, 2004.
2. Greene MH, Clark JW and Blayney DW: Epidemiology of ovarian cancer. Semin Oncol 11: 209-226, 1984.
3. Berek JS, Bertelsen K, du Bois A, et al: Epithelial ovarian cancer (advanced stage): consensus conference (1998). Gynecol Obstet Fertil 28: 576-583, 2000.
4. McGuire WP, Hoskins W, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996. (Pubitemid 26012496)
5. Dieras V, Bougnoux P, Petit T, et al: Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Ann Oncol 13: 258-266, 2002. (Pubitemid 34704978)
6. Tattersall MHN: Ovarian cancer chemotherapy: carboplatin as standard. Lancet 360: 500-501, 2002.
7. Ossenkoppele GJ: Treatment of multiple myeloma in elderly patients. New developments. Drugs Aging 11: 152-164, 1997.
8. Samuels BL and Bitran JD: High-dose intravenous melphalan: a review. J Clin Oncol 13: 1786-1799, 1995.
9. Sarosy G, Leyland-Jones B, Soochan P and Cheson BD: The systemic administration of intravenous melphalan. J Clin Oncol 6: 1768-1782, 1988. (Pubitemid 19089058)
10. Tattersall MH, Jarman M, Newlands ES, Holyhead L, Milstead RA and Weinberg A: Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14: 507-513, 1978. (Pubitemid 8336069)
11. Thigpen T, Vance R, Puneky L and Khansur T: Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55: S97-107, 1994.
12. Bosanquet AG and Bird MC: Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. Cancer Chemother Pharmacol 21: 211-215, 1988.
13. Pinguet F, Bressolle F, Culine S, et al: Influence of the schedule of exposure on the cytotoxic effect of melphalan on human 8226 and A2780 cells. Eur J Cancer 35: 1402-1406, 1999. (Pubitemid 29397443)
14. Pinguet F, Martel P, Rouanet P, Fabbro M and Astre C: Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm 51: 2701-2702, 1994.
15. Pinguet F, Culine S, Bressolle F, et al : A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res 6: 57-63, 2000. (Pubitemid 30064976)
16. Mougenot P, Pinguet F, Fabbro M, et al: Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol 53: 503-512, 2004. (Pubitemid 38680248)
17. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
18. Ozols RF, Schwartz PE and Eifel PJ: Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: Cancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). Lippincott Williams & Wilkins, Philadelphia, pp1597-1632, 2001.
19. Muggia F and Hamilton A: Phase III data on caelyx in ovarian cancer. Eur J Cancer 37 (Suppl 9): S15-18, 2001.
20. Ten Bokkel Huinink W, Lane SR, Ross GA and International Topotecan Study Group: Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15: 100-103, 2004.
21. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA and Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996. (Pubitemid 26337972)
22. McGuire WP, Rowinsky EK, Rosenheim NB, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279, 1989. (Pubitemid 19204753)
23. Im DD, McGuire WP and Rosenheim NB: Contemporary management of ovarian cancer. Obstet Gynecol Clin N Am 28: 759-773, 2001. (Pubitemid 33116265)
24. Christian J and Thomas H: Ovarian cancer chemotherapy. Cancer Treat Rev 27: 99-109, 2001. (Pubitemid 32499382)
25. Pater JL, Carmichael JA, Krepart GV, et al: Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 71: 277-281, 1987. (Pubitemid 17051729)
26. Omura GA, Morrow CP, Blessing JA, et al : Randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51: 783-789, 1983. (Pubitemid 13143151)
27. Young RC, Chabner BA, Hubbard SP, et al: Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299: 1261-1266, 1978. (Pubitemid 9115794)
28. Piver MS, Barlow JJ, Yazigi R and Blumenson LE: Melphalan chemotherapy in advanced ovarian carcinoma. Obstet Gynecol 51: 352-356, 1978. (Pubitemid 8283174)
29. Park RC, Blom J, Disaia PJ, Lagasse LD and Blessing JA: Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer 45: 2529-2542, 1980. (Pubitemid 10105306)
30. Brodovsky HS, Bauer M, Horton J and Elson PJ: Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. Cancer 53: 844-852, 1984. (Pubitemid 14183741)
31. Trope C: Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol 70: 582-586, 1987.
32. Wadler S, Yeap B, Vogl S and Carbone P: Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results - Eastern Cooperative Oncology Group Study E2878. Cancer 77: 733-742, 1996.
33. Rai KR, Holland JF, Glidewell RB et al : Treatment of acute myelocytic leukemia: a study by cancer and leukemia. Group B. Blood 58: 1203-1212, 1981. (Pubitemid 12251149)
34. Baker LH, Opipari MI, Wilson H, et al: Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer. Obstet Gynecol 52: 146-150, 1978. (Pubitemid 8381757)
35. Fraschini G, Yap HY, Hortobagyi GN, et al: Five-day continuous infusion vinblastine in the treatment of breast cancer. Cancer 56: 225-229, 1985. (Pubitemid 15031637)
36. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425-432, 1989. (Pubitemid 19098135)
37. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of relation between concentration and effect. N Engl J Med 341: 471-477, 1986.
38. Mitchell RB, Ratain MJ and Vogelzang NJ: Experimental rationale for continuous infusion chemotherapy. In: Concomitant continuous infusion chemotherapy and radiation. Rotman M and Rosenthal CJ (eds). Springer-Verlag, New York, pp41-58, 1991.
39. Posner M, Belliveau J, Weitberg A, et al: Continuous infusion cisplatil and bolus 5-fluorouracil in colorectal carcinoma. Cancer Res 71: 975-977, 1987. (Pubitemid 17151379)
40. Samuels BL, Vogelzang NJ, Ruane M, et al: Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 71: 971-972, 1987. (Pubitemid 17151377)
41. Jensen JL, Goel R and Venner PM: The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 65: 1291-1297, 1990. (Pubitemid 20097150)
42. Davis-Perry S, Hernandez E, Houck KL and Shank R: Melphalan for the treatment of patients with recurrent epithelial ovarian cancer. Am J Clin Oncol 26: 429-433, 2003. (Pubitemid 36962092)